Histogenics Corporation to Announce Second Quarter 2017 Financial Results on August 10, 2017
27 juil. 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., July 27, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the musculoskeletal...
Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference
26 juil. 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., July 26, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Announces Publication of Data From Collagen and Chondrocyte 3-D Bioprinting Study
11 juil. 2017 08h30 HE
|
Histogenics Corporation
– Findings Augment Growing Body of Information to Support the Manufacture of Current and Next-Generation NeoCart® Implants – – 3-D Bioprinting May Enable More Efficient Production of Next Generation...
Histogenics Completes Enrollment for Phase 3 Clinical Trial of Neocart® to Treat Knee Cartilage Damage
27 juin 2017 16h01 HE
|
Histogenics Corporation
– On Track for Top-Line One Year Superiority Data and Potential BLA Filing in Third Quarter of 2018 – – Novel Tissue Implant Potentially Accelerates Recovery and Reduces Pain through Proprietary...
Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer
05 juin 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., June 05, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation to Present at Upcoming Industry Conferences
16 mai 2017 08h30 HE
|
Histogenics Corporation
WALTHAM, Mass., May 16, 2017 (GLOBE NEWSWIRE) -- Histogenics Corporation (Histogenics) (Nasdaq:HSGX), a regenerative medicine company focused on developing and commercializing products in the...
Histogenics Corporation Receives Innovation Award
15 mai 2017 08h30 HE
|
Histogenics Corporation
‒ Histogenics Recognized by the Smaller Business Association of New England (SBANE) as One of the Most Innovative Companies in the Region ‒‒ NeoCart® and Tissue Generation Platform Seen as a Potential...
Histogenics Corporation Announces First Quarter 2017 Financial and Operating Results
11 mai 2017 06h30 HE
|
Histogenics Corporation
‒ NeoCart® Phase 3 Clinical Trial Enrollment Near Completion ‒‒ NeoCart Approval Pathway in Japan Defined After Successful Conclusion of Discussions with the Japan Pharmaceuticals and Medical Devices...
ヒストジェニックス、再生軟骨・ネオカートに対する日本における治験計画について、日本医薬品医療機器総合機構と同意に達したことを発表
08 mai 2017 18h00 HE
|
Histogenics Corporation
－ 米国での長期にわたる経験と多くのデータパッケージによって、日本において確認のための小規模治験が成功裏に完了すれば、日本におけるネオカート (NeoCart®) の製造販売承認が本承認で得られる見込みとなりました － 2017年第1四半期に日本医薬品医療機器総合機構との治験相談が完了し、そこでは、臨床、品質、非臨床安全性を含めた申請に必要なすべての分野が網羅されています －...
Histogenics Announces Agreement With the Japan Pharmaceuticals and Medical Devices Agency Regarding Japanese Regulatory Pathway for NeoCart®
08 mai 2017 06h30 HE
|
Histogenics Corporation
– Long history and significant US data package may enable full Marketing and Manufacturing Authorization of NeoCart subject to successful completion of small confirmatory clinical trial in Japan – –...